RIPK2 ALK2 Inhibitor Compounds for Signaling Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and inflammatory diseases, such as inflammatory bowel disease and multiple sclerosis, as well as bone diseases and cancers, lack effective inhibitors for protein kinases like RIPK2 and ALK2, which are involved in pro-inflammatory signaling and cellular pathways.
Innovation Solution
Development of compounds that inhibit protein kinases, specifically RIPK2 and ALK2, to target and modulate their signaling pathways, offering therapeutic benefits for various diseases by acting as dual inhibitors or preferentially inhibiting these enzymes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune and inflammatory diseases are used, then existing therapeutic options are available, but effective inhibition of protein kinases like RIPK2 and ALK2 is lacking
Solution Approach 1:
The patent employs parameter changes by modifying molecular structures of inhibitor compounds to optimize their binding affinity and selectivity for specific protein kinase targets (RIPK2 and ALK2). By adjusting chemical parameters such as substituent groups, molecular weight, and structural configuration, the compounds achieve enhanced therapeutic effectiveness while maintaining target specificity.
Solution Approach 2:
The patent creates dual inhibitors that can simultaneously target multiple protein kinases (RIPK2 and ALK2) with a single compound. This multi-functionality approach allows one inhibitor to address multiple disease pathways, providing versatile therapeutic benefits for various conditions including autoimmune diseases, inflammatory disorders, bone diseases, and cancers.
2Adaptability or versatility
If dual inhibitors for RIPK2 and ALK2 are developed, then broader therapeutic benefits are achieved, but compound design complexity increases
Solution Approach 1:
The patent merges the inhibitory activities for RIPK2 and ALK2 into single compound molecules. By combining functional groups and structural elements that confer activity against both kinases, the invention creates dual inhibitors that achieve broad therapeutic coverage without requiring separate compounds for each target.
Solution Approach 2:
The patent applies local quality by introducing specific functional groups and structural modifications at particular positions within the inhibitor molecules. These localized structural features are designed to interact with specific residues in the ATP-binding pockets of RIPK2 and ALK2, enabling selective dual inhibition through targeted molecular interactions.
Data Source
AI summary
Identified compounds demonstrate protein kinase inhibitory activity and inhibition of dependent cell signaling pathways, such as NOD2 cell signaling. More specifically, the compounds are demonstrated to inhibit receptor interacting kinase 2 (RIPK2) and/or Activin-like kinase 2 (ALK2). Compounds that are either dual RIPK2/ALK2 inhibitors or that preferentially inhibit RIPK2 or ALK2 could provide therapeutic benefit.